baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC Put 2300 TDXP 20.12.2024/ DE000HS2Z518 /

09/07/2024 08:23:26	Chg.0.000	Bid22:00:10	Ask22:00:10	Underlying	Strike price	Expiration date	Option type
0.075EUR	0.00%	- Bid Size: -	- Ask Size: -	TECDAX	2,300.00 EUR	20/12/2024	Put

GlobeNewswire 14/05 CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

GlobeNewswire 23/01 Bluebeam Harnesses the Power of AI and Customer Passion to Drive Innovation in the Built World

GlobeNewswire 11/12/2023 Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...

GlobeNewswire 07/11/2023 Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

GlobeNewswire 05/09/2023 Bluebeam Announces New Executive Leadership Appointments

GlobeNewswire 12/06/2018 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...

GlobeNewswire 20/12/2016 Medigene announces outlicensing of AAVLP technology

GlobeNewswire 13/12/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...

GlobeNewswire 06/12/2016 Medigene AG to be included in TecDAX Index

GlobeNewswire 06/12/2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...

GlobeNewswire 06/12/2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016

GlobeNewswire 28/11/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...

GlobeNewswire 17/11/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...

GlobeNewswire 15/11/2016 MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 15/11/2016 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 15/11/2016 MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 15/11/2016 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 15/11/2016 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...

GlobeNewswire 14/11/2016 MorphoSys to Present at Upcoming Investor Conferences

GlobeNewswire 08/11/2016 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations

GlobeNewswire 07/11/2016 MorphoSys AG Reports Results for the First Nine Months of 2016

GlobeNewswire 03/11/2016 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...

GlobeNewswire 02/11/2016 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...

GlobeNewswire 28/10/2016 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

GlobeNewswire 20/10/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

HSBC Put 2300 TDXP 20.12.2024/ DE000HS2Z518 /

If you wish to receive reply to your feedback, please provide your email address.